Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer (NCT01142388)
Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer
🩺 Plain-English Summary (8th-Grade Level)
This randomized phase II trial studies how well paclitaxel with or without cixutumumab works in treating patients with esophageal cancer or gastroesophageal junction cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cixutumumab may kill cancer cells by blocking the action of a protein needed for cancer cell growth. Giving paclitaxel with or without cixutumumab may kill more tumor cells.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic in Arizona — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (232 Sites)
Showing the first 25 of 232 sites.
- Mayo Clinic in Arizona — Scottsdale, Arizona
- Stanford Cancer Institute Palo Alto — Palo Alto, California
- The Medical Center of Aurora — Aurora, Colorado
- Boulder Community Foothills Hospital — Boulder, Colorado
- Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
- AdventHealth Porter — Denver, Colorado
- Presbyterian - Saint Lukes Medical Center - Health One — Denver, Colorado
- Saint Joseph Hospital - Cancer Centers of Colorado — Denver, Colorado
- Rose Medical Center — Denver, Colorado
- Western States Cancer Research NCORP — Denver, Colorado
- Swedish Medical Center — Englewood, Colorado
- Saint Mary's Hospital and Regional Medical Center — Grand Junction, Colorado
- Banner North Colorado Medical Center — Greeley, Colorado
- CommonSpirit Saint Anthony Hospital Cancer Center — Lakewood, Colorado
- AdventHealth Littleton — Littleton, Colorado
- Sky Ridge Medical Center — Lone Tree, Colorado
- Longmont United Hospital — Longmont, Colorado
- Banner North Colorado Medical Center - Loveland Campus — Loveland, Colorado
- AdventHealth Parker — Parker, Colorado
- Saint Mary Corwin Medical Center — Pueblo, Colorado
- North Suburban Medical Center — Thornton, Colorado
- Intermountain Health Lutheran Hospital — Wheat Ridge, Colorado
- Smilow Cancer Hospital Care Center at Saint Francis — Hartford, Connecticut
- Beebe Medical Center — Lewes, Delaware
- Christiana Care Health System-Christiana Hospital — Newark, Delaware
📞 Contact the Study Coordinator
Phone: (800) 664-4580
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Esophageal Adenocarcinoma
Explore by condition: All Metastatic Esophageal Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.